DEVELOPMENT OF PERSONALIZED TARGETED THERAPIES FOR THE TREATMENT OF LUNG CANCER

Abstract

The development of personalized targeted therapies for the treatment of lung cancer has been a field of intense research and innovation in contemporary oncology. This integrative review explored the evolution of targeted therapies, highlighting the importance of genetic biomarkers in the personalization of treatment. Mutations in the EGFR, ALK, ROS1 and other genes have been identified as critical determinants of therapeutic response, driving the development of specific tyrosine kinase inhibitors and other targeted therapies. Furthermore, the combination of targeted therapies with immunotherapy has emerged as a promising strategy to improve clinical outcomes, although challenges such as acquired resistance and accessibility to new technologies persist. The successful implementation of these therapies depends not only on continued scientific advances, but also on clinical infrastructures and health policies that support the widespread adoption of genetic testing and equitable access to treatments. In conclusion, personalized targeted therapies represent a significant advance in the treatment of lung cancer, potentially offering improved clinical outcomes and quality of life for patients affected by this complex disease.